(NP (NP (VBN Increased) (NP-COOD (NP (NN proliferation)) (, ,) (NP (NN cytotoxicity)) (, ,) (CC and) (NP (NN gene) (NN expression)))) (PP-TMP (IN after) (NP (NP (NN stimulation)) (PP (IN of) (NP (JJ human) (JJ peripheral) (NN blood) (NN T) (NNS lymphocytes))) (PP (IN through) (NP (NP (DT a) (NN surface) (NN ganglioside)) (PRN (-LRB- -LRB-) (NP (NN GD3)) (-RRB- -RRB-)))))) (PRN (-LRB- -LCB-) (S (NP-SBJ (VBN published) (NN erratum)) (VP (VBZ appears) (PP (IN in) (NP (NP (NNP J) (NNP Immunol)) (NP-TMP (CD 1994) (NNP Jul) (CD 15)) (: ;) (NP (CD 153) (-LRB- -LRB-) (CD 2) (-RRB- -RRB-)) (: :) (NP (CD 910)))))) (-RRB- -RCB-)))
(S (NP-SBJ (JJ Previous) (NNS studies)) (VP (VBP have) (VP (VBN suggested) (SBAR (IN that) (S (NP-SBJ (NNS gangliosides)) (VP (VBP have) (NP (DT an) (JJ important) (NN role)) (PP (IN in) (NP (NN cell) (NP-COOD (NP (NN signaling)) (CC and) (NP (NN recognition)))))))))) (. .))
(S (ADVP (RB However)) (, ,) (NP-SBJ-13 (NP (PRP$ their) (JJ specific) (NN function)) (PP (IN in) (NP (DT these) (NNS processes)))) (VP (VBZ has) (RB not) (VP (VBN been) (ADVP (RB clearly)) (VP (VBN defined) (NP (-NONE- *-13))))) (. .))
(S (NP-SBJ-14 (NP (NP (DT A) (NN mAb)) (, ,) (NP (NN R24)) (, ,)) (SBAR (WHNP-15 (WDT that)) (S (NP-SBJ (-NONE- *T*-15)) (VP (VBZ reacts) (ADVP (RB specifically)) (PP (IN with) (NP (NP (DT a) (NN cell) (NN surface) (NN ganglioside)) (PRN (-LRB- -LRB-) (NP (NN GD3)) (-RRB- -RRB-)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN demonstrated) (S (NP-SBJ (-NONE- *-14)) (VP (TO to) (VP (VB stimulate) (NP (NP (NN proliferation)) (PP (IN of) (NP (NP (NN T) (NNS cells)) (VP (VBN derived) (NP (-NONE- *)) (PP (IN from) (NP (JJ human) (JJ peripheral) (NN blood))))))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN investigated) (NP (NP (DT the) (NNS mechanisms)) (SBAR (WHPP-16 (IN by) (WHNP (WDT which))) (S (NP-SBJ (DT the) (NN R24) (NN mAb)) (VP (VBZ affects) (NP (NN T) (NN cell) (NNS functions)) (PP (-NONE- *T*-16)))))))) (. .))
(S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN observed) (SBAR (IN that) (S (NP-SBJ (DT the) (NN R24) (NN mAb)) (VP (VBZ stimulates) (NP (NP (JJ GD3+) (NN T) (NN cell) (NP-COOD (NP (NN proliferation)) (, ,) (NP (NN cytotoxicity)) (, ,) (CC and) (NP (NN surface) (NN marker) (NN expression)))) (PP (IN of) (NP-COOD (NP (NN IL-2R) (NN alpha-chain)) (, ,) (NP (NN IL-2R) (NN beta-chain)) (, ,) (NP (NN HLA-DR)) (, ,) (NP (NN CD11a)) (, ,) (CC and) (NP (NN CD11c)))))))))) (. .))
(S (ADVP (RB Additionally)) (, ,) (NP-SBJ-COOD (NP (NN IFN-gamma) (NN activity)) (CONJP (CC but) (RB not)) (NP (NP-COOD (NP (NN IL-1)) (, ,) (NP (NN IL-2)) (, ,) (CC or) (NP (NN IL-4))) (NN activity))) (VP (VBD was) (ADJP-PRD (JJ present) (PP (IN in) (NP (NN culture) (NNS supernatants)))) (PP-TMP (NP (CD 72) (NN h)) (IN after) (NP (NN R24) (NN stimulation)))) (. .))
(S (PP (IN In) (NP (DT some) (NNS donors))) (, ,) (NP-SBJ-17 (VBN increased) (NP-COOD (NP (NN IL-6)) (CC and) (NP (NN TNF-alpha))) (NN activity)) (ADVP (RB also)) (VP (VBD was) (VP (VBN detected) (NP (-NONE- *-17)) (PP-TMP (IN after) (NP (NN R24) (NN treatment))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NN R24) (NN treatment)) (VP (VBD resulted) (PP (IN in) (NP-COOD (NP (NP (NN translocation)) (PP (IN of) (NP-COOD (NP (NN c-rel)) (, ,) (CC but) (NP (ADJP-COOD (ADJP (JJ little)) (CC or) (ADJP (DT no))) (NN NF) (NN kappa) (NN B) (NP-COOD (NP (NN p50)) (CC or) (NP (NN p65)))) (, ,))) (PP (IN from) (NP (DT the) (NN cytoplasm))) (PP (TO to) (NP (DT the) (NN nucleus)))) (CC and) (NP (NP (DT an) (NN increase)) (PP (IN of) (NP (NP (ADJP (NN NF) (NN kappa) (NN B) (NN binding)) (NNS complexes)) (VP (VBG containing) (NP-COOD (NP (NN c-rel)) (CC and) (NP (NN p50)))))))))) (. .))
(S (NP-SBJ (DT This) (NN treatment)) (ADVP (RB also)) (VP (VBD caused) (NP (NP (VBN increased) (NN tyrosine) (NN phosphorylation)) (PP (IN of) (NP (JJ specific) (NN protein) (NNS substrates))))) (. .))
(S (NP-SBJ-18 (NP (JJ R24-stimulated) (NNS increases)) (PP (IN in) (NP-COOD (NP (NN proliferation)) (, ,) (NP (NN cytotoxicity)) (, ,) (CC and) (NP (NN cell) (NN surface) (NN protein) (NN expression))))) (VP (MD could) (VP (VB be) (VP (VBN blocked) (NP (-NONE- *-18)) (PP (IN by) (NP-LGS-COOD (NP (NN cyclosporin)) (CC and) (NP (NN staurosporin)))) (, ,) (S (NP-SBJ (-NONE- *)) (VP (VBG indicating) (SBAR (IN that) (S (NP-SBJ-COOD-20 (NP (NN (calcineurin cyclophilin))) (CC and) (NP (NN protein) (NN kinase) (NN C))) (VP (MD may) (VP (VB be) (VP (VBN involved) (NP (-NONE- *-20)) (PP (IN in) (NP (DT the) (NN R24) (NN signaling) (NN pathway))))))))))))) (. .))
(S (ADVP (RB Additionally)) (, ,) (NP-SBJ (NP (NN herbimycin) (NN A)) (, ,) (NP (DT a) (NN tyrosine) (NN kinase) (NN inhibitor)) (, ,)) (VP (VBD blocked) (NP (NP (DT the) (JJ R24-stimulated) (NN increase)) (PP (IN in) (NP-COOD (NP (NN proliferation)) (CONJP (CC but) (RB not)) (NP (NN cytotoxicity))))) (PP (IN at) (NP (NP (NNS concentrations)) (ADJP (JJ consistent) (PP (IN with) (NP (NP (NN specificity)) (PP (IN for) (NP (NN tyrosine) (NNS kinases))))))))) (. .))
(S (NP-SBJ (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ-21 (JJ multiple) (JJ biochemical) (NNS pathways)) (VP (VBP are) (VP (VBN involved) (NP (-NONE- *-21)) (PP (IN in) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (JJ human) (NN T) (NNS cells))) (PP (IN by) (NP (NN R24)))))))))) (. .))
